Q2 Earnings Estimate for HURA Issued By HC Wainwright

TuHURA Biosciences (NASDAQ:HURA) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of TuHURA Biosciences in a note issued to investors on Monday, March 3rd. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.20) for the quarter. HC Wainwright has a “Buy” rating and a $13.00 price target on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.10) EPS and Q2 2026 earnings at ($0.11) EPS.

Several other equities research analysts have also recently weighed in on the company. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Rodman & Renshaw started coverage on TuHURA Biosciences in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company.

TuHURA Biosciences Stock Performance

HURA opened at $2.11 on Thursday. TuHURA Biosciences has a 1 year low of $1.89 and a 1 year high of $14.60. The stock’s 50 day moving average is $4.13.

Institutional Investors Weigh In On TuHURA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Jefferies Financial Group Inc. purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $54,000. Squarepoint Ops LLC purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $223,000. OMERS ADMINISTRATION Corp purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $128,000. Millennium Management LLC purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $138,000. Finally, Bank of America Corp DE purchased a new position in shares of TuHURA Biosciences in the 4th quarter valued at approximately $59,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.